<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27309" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Plasmodium falciparum Malaria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zekar</surname>
            <given-names>Lara</given-names>
          </name>
          <aff>General Hospital Celje</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharman</surname>
            <given-names>Tariq</given-names>
          </name>
          <aff>Southern Ohio Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lara Zekar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tariq Sharman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27309.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Malaria is a global infectious disease that remains a leading cause of morbidity and mortality in the developing world. Severe and fatal malaria is predominantly caused by Plasmodium falciparum. Its management and prognosis depend on the awareness of a possible diagnosis in travelers returning from endemic areas, early recognition, and timely effective treatment. This activity reviews the evaluation and management of patients with falciparum malaria and explains the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of P. falciparum infection.</p></list-item><list-item><p>Summarize the findings seen in a patient with P. falciparum malaria.</p></list-item><list-item><p>Describe common complications for patients with severe P. falciparum malaria.</p></list-item><list-item><p>Outline the importance of communication and collaboration among the interdisciplinary team to enhance the delivery of care and improve outcomes for patients affected by P. falciparum malaria.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27309&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27309">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27309.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Malaria is a mosquito-borne disease caused by five protozoa: <italic toggle="yes">Plasmodium falciparum</italic>, <italic toggle="yes">P. vivax</italic>, <italic toggle="yes">P. malariae</italic>, <italic toggle="yes">P. ovale,</italic> and most recently implicated <italic toggle="yes">P.knowlesi</italic>. Infection with <italic toggle="yes">P. falciparum</italic> is being accounted for more than 90% of the world&#x02019;s malaria mortality and therefore remains an important threat to public health on a global scale.<xref ref-type="bibr" rid="article-27309.r1">[1]</xref><xref ref-type="bibr" rid="article-27309.r2">[2]</xref>&#x000a0;The World Health Organization (WHO) World Malaria report 2019 estimates 228 million cases of malaria worldwide, causing 405 000 deaths in the year 2018, many under the age of 5. Malaria is endemic in more than 90 countries, affecting approximately 40% of the world&#x02019;s population.<xref ref-type="bibr" rid="article-27309.r2">[2]</xref>&#x000a0;There is a significant number of cases of imported malaria and local transmission following importation occurring in non-malarial countries, including North America and Europe.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref>&#x000a0;Malaria is associated with travelers to the endemic areas, and increasing numbers of imported malaria necessitate an understanding of frequently non-specific symptoms, difficulties related to the malarial diagnosis, and treatment possibilities.<xref ref-type="bibr" rid="article-27309.r2">[2]</xref></p>
      </sec>
      <sec id="article-27309.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Five species of genus <italic toggle="yes">Plasmodium</italic> are known to cause malaria in humans. The vector for<italic toggle="yes"> Plasmodium spp.</italic> is a female A<italic toggle="yes">nopheles</italic> mosquito that inoculates sporozoites contained in her salivary glands into the puncture wound when feeding.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref>&#x000a0;Sporozoites enter peripheral bloodstream and are uptaken by hepatocytes, where they undergo an asexual pre-erythrocytic liver-stage as liver schizonts lasting up to 2 weeks before the onset of the blood stage.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r4">[4]</xref>&#x000a0;As they replicate within hepatocytes, they form motile merozoites that are subsequently released into the bloodstream, where they invade red blood cells (RBC). The process continues through serial cycles of asexual replication of merozoites that go through ring, trophozoite, and schizont stages before forming and releasing new invasive daughter merozoites that consequently infect new RBC, therefore causing a rise in parasite numbers.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r5">[5]</xref>&#x000a0;<italic toggle="yes">P. falciparum</italic> produces high levels of blood-stage parasites and is known to modify the surface of the infected RBC, creating an adhesive phenotype, e.g. (sticky cell) causing RBC sequestration inside small and middle-sized vessels, removing the parasite from the circulation for nearly half of the asexual cycle.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref>&#x000a0;Sequestration leads to splenic parasite clearance avoidance, host cell endothelial damage, and microvascular obstruction.<xref ref-type="bibr" rid="article-27309.r5">[5]</xref><xref ref-type="bibr" rid="article-27309.r6">[6]</xref>&#x000a0;A small fraction of intra-erythrocytic parasites switch to sexual development, producing morphologically distinct male and female gametocytes that reach the host's dermis and are ingested by a mosquito, rendering it infectious to humans.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r4">[4]</xref><xref ref-type="bibr" rid="article-27309.r5">[5]</xref>&#x000a0;After ingestion by a female A<italic toggle="yes">nopheles</italic> mosquito, the male micro-gametocytes go through a process of ex-flagellation in the mosquito's midgut, fusing with female macro-gametes to form a zygote. The zygote then reaches the stage of ookinete that migrates through a thin wall, matures into oocyst, producing and upon rupturing, releasing numerous sporozoites that are dispersed throughout mosquitos body, including salivary glands, therefore completing the lifecycle. Gametocytes are hence of vital importance to the transmission cycle of malaria.<xref ref-type="bibr" rid="article-27309.r2">[2]</xref><xref ref-type="bibr" rid="article-27309.r4">[4]</xref><xref ref-type="bibr" rid="article-27309.r7">[7]</xref>&#x000a0;The clinical symptoms are, however, predominantly a result of the asexual stages of parasite replication in human blood.<xref ref-type="bibr" rid="article-27309.r5">[5]</xref></p>
      </sec>
      <sec id="article-27309.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<italic toggle="yes">
<bold>Worldwide&#x000a0;</bold>
</italic>
</p>
        <p>WHO World Malaria Report 2019 states that an estimated 228 million cases of malaria occurred worldwide in 2018, and reports steadily decreasing the number of cases since 2010. In 2018, nineteen sub-Saharan African countries and India carried approximately 85% of the global malaria burden. The most prevalent and pathogenic malaria parasite, most commonly associated with severe illness and death, especially in the WHO African region, accounting for 99.7% malaria cases, is<italic toggle="yes"> P. falciparum.</italic><xref ref-type="bibr" rid="article-27309.r8">[8]</xref>&#x000a0;<italic toggle="yes">P. falciparum</italic> is also highly prevalent in South-East Asia, Eastern Mediterranean, and Western Pacific regions.&#x000a0;The most vulnerable groups affected by malaria in high-transmission areas are children younger than 5 years old, their deaths accounting for 67% of global malaria deaths, and primigravidae. In low transmission areas, all ages are at risk due to low immunity.<xref ref-type="bibr" rid="article-27309.r2">[2]</xref></p>
        <p>
<italic toggle="yes">
<bold>The United States&#x000a0;</bold>
</italic>
</p>
        <p>Most malaria cases diagnosed in the United States of America are imported from endemic countries.<xref ref-type="bibr" rid="article-27309.r9">[9]</xref>&#x000a0;The risk of infection depends on the length of exposure and the intensity of malaria transmission in the geographical region.<xref ref-type="bibr" rid="article-27309.r10">[10]</xref>&#x000a0;During 2015 CDC received 1517 reports of confirmed malaria in the United States of America, one of the cases was classified as congenital, 1485 were imported from endemic countries, and 31 reports had an incomplete travel history. The 12.1% decrease of imported malaria in 2015 correlates with the decrease in the number of cases imported from West Africa, possibly due to altered travel because of the Ebola epidemic. However, the overall trend shows that, on average additional 29 cases of malaria are reported every year since 1973, coinciding with an increasing number of international travel. Among the cases with species determination, the majority were <italic toggle="yes">P. falciparum</italic>, accounting for 86.6% cases from Africa, 70.9% from Central America, 20.8% from South America, and 4.8% from Asia<italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-27309.r8">[8]</xref>&#x000a0;</p>
        <p>Based on present predictions for climate change, researchers predict an increase in the geographical distribution of malaria and an increasingly suitable climate for malaria transmission in tropical regions.<xref ref-type="bibr" rid="article-27309.r11">[11]</xref>&#x000a0;However, several other determinates factor in the epidemiology of malaria other than global warming: such as politics, economic development, urbanization, and population growth, migration changes, etc.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r11">[11]</xref>&#x000a0;Additionally, there is an impending threat of artemisinin- and multidrug-resistant <italic toggle="yes">P. falciparum</italic>, particularly prevalent in Greater Mekong Subregion (GMS), causing high failure rates of artemisinin-combination therapies.<xref ref-type="bibr" rid="article-27309.r12">[12]</xref><xref ref-type="bibr" rid="article-27309.r3">[3]</xref></p>
        <p>
<italic toggle="yes">
<bold>General Epidemiology and Risk Groups</bold>
</italic>
</p>
        <p>Severe malaria occurs in patients with no or little effective immunity. In parts of the world with the stable and intense transmission of <italic toggle="yes">P. falciparum</italic>, severe malaria is mostly a disease of the pediatric population younger than 5 years, as specific acquired immunity develops with age (due to repeated infections), providing increased, although incomplete, protection in older children and adults. Severe malaria can, however, occur at any age in areas with low or/and unstable transmission rates and individuals with no-immunity (e.g., travelers to the endemic areas).<xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;Susceptibility to malarial infections increases during pregnancy.<xref ref-type="bibr" rid="article-27309.r14">[14]</xref>&#x000a0;Pregnant women in the second trimester are at the greatest risk of infection, although the risk is somewhat affected by age and gravidity, with young primigravidae being at the highest risk at high transmission areas.<xref ref-type="bibr" rid="article-27309.r15">[15]</xref>&#x000a0;Women living in areas with unstable and low malaria transmission rates are infected infrequently and therefore lack the immunity, which often causes a rapid progression to severe malaria and death.<xref ref-type="bibr" rid="article-27309.r14">[14]</xref></p>
      </sec>
      <sec id="article-27309.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The rupture of the first liver schizont and the release of motile merozoites into peripheral circulation to invade red blood cells marks the start of a possible symptomatic infection. The first rupture and invasion are usually silent in most infected patients, but as the asexual cycle repeats itself in the next 24 to 48 hours, parasitemia rises, and immune response increases accordingly. It is usually associated with an increase of TNF alpha and other inflammatory markers in the cascade, including interleukin 10 (IL-10) and interferon-gamma (IFN-gamma).<xref ref-type="bibr" rid="article-27309.r6">[6]</xref>&#x000a0;Higher parasitemias are generally associated with a more severe clinical picture, but the relationship is very variable.<xref ref-type="bibr" rid="article-27309.r16">[16]</xref>&#x000a0;</p>
        <p>The most important virulence determinant in <italic toggle="yes">P. falciparum</italic> infection is the parasite&#x000b4;s ability to modify the surface of the infected red blood cell, thus creating an adhesive phenotype. The cytoadhesion is mediated through the <italic toggle="yes">P. falciparum</italic> erythrocyte membrane protein 1(PfEMP1) family, which is the product of var gene transcription. There is immense diversity in var genes in the parasite population, which has recently been a focus of research, due to its suggested association between increased transcription of specific var genes and the development of severe malaria.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref><xref ref-type="bibr" rid="article-27309.r17">[17]</xref>&#x000a0;The cytoadherence of mature-staged infected RBC to the endothelium, platelets, and uninfected red blood cells causes sequestration in the microvasculature of various organs, resulting in microcirculation obstruction, impaired tissues perfusion, lactic acidosis and consequently, end-organ damage.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref><xref ref-type="bibr" rid="article-27309.r19">[19]</xref><xref ref-type="bibr" rid="article-27309.r20">[20]</xref>&#x000a0;Prominent sequestration occurs in the placenta during pregnancy, causing low birth weight, anemia, miscarriage, and congenital malaria.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref><xref ref-type="bibr" rid="article-27309.r19">[19]</xref></p>
        <p>In essence, the key features that render a fatal disease are the sequestration of<italic toggle="yes"> P. falciparum</italic> in tissues, in conjunction with the up-regulation of cytokines and other toxic substances and an absence or an untimely provision of effective antimalarial therapy.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref></p>
      </sec>
      <sec id="article-27309.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Malaria is a complex disease with a spectrum of clinical effects that not only differ between children and adults but can range from practically none in patients with asymptomatic parasitemia, to uncomplicated malaria, through to severe and possibly lethal malaria.<xref ref-type="bibr" rid="article-27309.r20">[20]</xref>&#x000a0;The mean incubation period for <italic toggle="yes">P. falciparum</italic> is 12 days, with most patients presenting in the first or second month after exposure in endemic areas.<xref ref-type="bibr" rid="article-27309.r21">[21]</xref><xref ref-type="bibr" rid="article-27309.r22">[22]</xref>&#x000a0;It is key to take a detailed travel history in any patient with fever or history of fever, as malaria is a crucial diagnosis to consider in any individual who has traveled to a malaria-endemic area.<xref ref-type="bibr" rid="article-27309.r22">[22]</xref><xref ref-type="bibr" rid="article-27309.r21">[21]</xref></p>
        <p>
<bold>Uncomplicated <italic toggle="yes">P. falciparum</italic>&#x000a0;Malaria&#x000a0;</bold>
</p>
        <p>Malaria can be separated into two disease presentations: uncomplicated and severe.&#x000a0;<xref ref-type="bibr" rid="article-27309.r4">[4]</xref>&#x000a0;The WHO defines the presence of symptoms without clinical or laboratory signs to indicate severity or vital organ dysfunction as uncomplicated malaria.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref>&#x000a0;Symptoms are generally non-specific, including fever, chills, myalgia, headache, anorexia, and cough, making clinical diagnosis unreliable.<xref ref-type="bibr" rid="article-27309.r4">[4]</xref><xref ref-type="bibr" rid="article-27309.r21">[21]</xref>&#x000a0;Patients occasionally present with gastrointestinal symptoms, respiratory symptoms, and jaundice.<xref ref-type="bibr" rid="article-27309.r22">[22]</xref>&#x000a0;The classical malarial paroxysms with spiking fever, chills, and rigors occurring at specific intervals are relatively uncommon, but if present, indicate an infection with <italic toggle="yes">P. ovale</italic> or <italic toggle="yes">P. vivax</italic>.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref>&#x000a0;Progression to severe or ultimately fatal disease is largely confined to<italic toggle="yes"> P. falciparum</italic> infections, although only a small percentage, approximately 1% to 2% of infections, lead to severe malaria.<xref ref-type="bibr" rid="article-27309.r20">[20]</xref><xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;Features of a severe disease usually appear after 3 to 7 days of the abovementioned non-specific symptoms, although there are some reports of rapid deterioration, failure to recover consciousness after a grand-mal seizure, and non-immune patients dying within 24 hours of their first symptom.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
        <p>
<bold>Severe <italic toggle="yes">P. falciparum</italic>&#x000a0;Malaria</bold>
</p>
        <p>The patient presenting with at least one of the clinical or laboratory features listed below, with asexual <italic toggle="yes">P. falciparum</italic> parasitemia (either detected in the peripheral blood smear or confirmed with rapid diagnostic test) and no other confirmed cause of his symptoms, classifies as suffering from severe malaria.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r23">[23]</xref>&#x000a0;Although<italic toggle="yes"> P. falciparum</italic> is responsible for the majority of the cases of severe malaria, it is also, albeit rarely, observed with <italic toggle="yes">P. vivax</italic> and <italic toggle="yes">P. knowlesi</italic> infections.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref><xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
        <p>A shortened list of danger signs is used for rapid clinical assessment, which includes prostration, respiratory distress (acidotic breathing), and impaired consciousness.<xref ref-type="bibr" rid="article-27309.r4">[4]</xref>&#x000a0;Other clinical manifestations of severe malaria include multiple convulsions, radiologically confirmed pulmonary edema (respiratory failure due to acute lung injury progressing to acute respiratory distress syndrome), abnormal bleeding (disseminated intravascular coagulation), acute kidney injury, jaundice, shock, and coma.<xref ref-type="bibr" rid="article-27309.r4">[4]</xref><xref ref-type="bibr" rid="article-27309.r21">[21]</xref><xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;Laboratory features in severe malaria can show severe anemia, hypoglycemia, acidosis, hyperlactatemia, renal impairment, and hyperparasitemia<bold>.</bold><xref ref-type="bibr" rid="article-27309.r13">[13]</xref><bold>&#x000a0;</bold>A comprehensive list of diagnostic criteria for falciparum malaria is shown in Table 1 - Diagnostic criteria for severe <italic toggle="yes">P. falciparum</italic> malaria.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Physical examination is usually unremarkable, especially of patients with uncomplicated malaria. They frequently present with irregular and erratic fever, reaching up to 41&#x000b0;C, sometimes accompanied by agitation or confusion.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;Mild spontaneously resolving jaundice can sometimes be seen in patients with otherwise-uncomplicated falciparum malaria. <xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r22">[22]</xref>&#x000a0;Other physical signs can include anemia and postural hypotension.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;In some cases, patients can present with tender hepatosplenomegaly after some days. However, a palpable spleen is particularly common in otherwise healthy populations in endemic areas, reflecting repeated infections.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref>&#x000a0;The comprehensive list of clinical features associated with severe malaria is shown in Table 1 - Diagnostic criteria for severe&#x000a0;<italic toggle="yes">P. falciparum</italic>&#x000a0;malaria.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;</p>
        <p>
<bold>Children</bold>
</p>
        <p>Children are more likely to present with non-specific and gastrointestinal symptoms such as fever, lethargy, malaise, nausea, vomiting, abdominal cramps, and somnolence.<xref ref-type="bibr" rid="article-27309.r22">[22]</xref>&#x000a0;They are more likely to develop hepatomegaly, splenomegaly, and severe anemia without major organ dysfunction than adults. In a case of severe malaria, they present with more frequent seizures (in 60% to 80%), hypoglycemia, and concomitant sepsis but are less likely to develop pulmonary edema and renal failure than adults.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Pregnant Women</bold>
</p>
        <p>The clinical features of infection in pregnancy vary from asymptomatic to severe, depending on the degree of (incomplete) immunity that a woman had acquired by the time she got pregnant. In semi-immune pregnant women, only a few infections result in fever or other symptoms.<xref ref-type="bibr" rid="article-27309.r15">[15]</xref>&#x000a0;Malaria in pregnancy has a devastating effect not only on maternal health but has been associated with increased infant mortality due to low birth weight caused by either intrauterine growth restriction or preterm labor or both.<xref ref-type="bibr" rid="article-27309.r15">[15]</xref>&#x000a0;<italic toggle="yes">P. falciparum</italic> infections are proven to be associated with complications such as maternal anemia, low birth weight, miscarriage, stillbirths, and congenital malaria.<xref ref-type="bibr" rid="article-27309.r6">[6]</xref><xref ref-type="bibr" rid="article-27309.r15">[15]</xref>&#x000a0;It is more likely for a pregnant woman in the second or third trimester to develop severe malaria with complications such as hypoglycemia and pulmonary edema, compared to non-pregnant adults.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
      </sec>
      <sec id="article-27309.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Once malaria is considered a possible diagnosis, it is important to facilitate immediate laboratory testing.<xref ref-type="bibr" rid="article-27309.r4">[4]</xref>&#x000a0;It is essential to distinguish between non-falciparum and falciparum malaria.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref>&#x000a0;As per the Centers for Disease Control and Prevention (CDC) guidelines, malaria should be routinely suspected in any febrile patient that has a recent history of travel to the endemic areas. The clinical features of either uncomplicated or severe malaria are non-specific, therefore requiring diagnosis by microscopy or rapid diagnostic test (RDT).<xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;The results should be communicated back to the requesting doctor as soon as possible, ideally within a few hours.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref></p>
        <p>A full blood count, urea, creatinine and electrolytes, blood glucose level, and liver function tests should be routinely performed. Thrombocytopenia suggests both <italic toggle="yes">non-falciparum</italic> and <italic toggle="yes">falciparum</italic> malaria infections in non-immune adults and children. In severely ill patients, additional studies such as blood gases, blood culture, lactate, and clotting studies are appropriate. In patients with fever and impaired consciousness, one should consider a lumbar puncture to exclude meningitis.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref></p>
        <p>The golden standard for diagnosis is a<bold> microscopic analysis of thick and thin blood smears.</bold> Thick smears allow for a sensitive parasitemia quantification, as parasitemias as low as 30-50/microL can be detected, while thin smears enable a determination of the <italic toggle="yes">Plasmodium</italic> species, prognostic assessment based on the staging of parasite development and estimation of the proportion of neutrophils containing malaria pigment.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;Three sets of thick and thin blood films spaced 12 to 24 hours apart should be performed by experienced laboratory personnel before a clinician can confidently rule out malaria.<xref ref-type="bibr" rid="article-27309.r8">[8]</xref>&#x000a0;</p>
        <p>Perceived peripheral blood parasitemia varies greatly in patients with severe malaria, due to the sequestration of the infected red blood cells in tissues.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;Although severe malaria can present with low parasite count, high counts are associated with increased risk of deterioration and subsequent treatment failure even without signs or symptoms of severity.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;More than 2% of parasitized RBC suggests an increased chance of developing severe disease, and parasitemia over 10% is considered as one of the diagnostic criteria for severe disease and is associated with increased mortality.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref>&#x000a0;Furthermore, in severe falciparum malaria, poor outcomes can be predicted by the presence of late-stage parasites in RBC and more than 5% of the neutrophils containing pigment.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Rapid diagnostic tests</bold> are commonly used in addition to blood slides and are useful alternatives in settings where a microscopic diagnosis is non-reliable or infeasible.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref><xref ref-type="bibr" rid="article-27309.r9">[9]</xref>&#x000a0;It is, however, recommended that all the RDTs should be followed by microscopy for confirmation and, if positive, quantification of parasitemia.<xref ref-type="bibr" rid="article-27309.r9">[9]</xref>&#x000a0;They are immune-chromatographic tests that most commonly identify either malaria antigens (e.g., <italic toggle="yes">P. falciparum</italic> histidine-rich-protein 2 (PfHRP2)) or enzyme called <italic toggle="yes">Plasmodium</italic> lactate dehydrogenase (pLDH). Tests have several downfalls as they cannot provide quantitative results, can stay positive months after infection with <italic toggle="yes">P. falciparum,</italic> or are, if testing for pLDH, positive only while there are living parasites in the blood.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;</p>
        <p>Polymerase chain reaction (PCR) is one of the possible diagnostic modalities but is, even if promptly available, too timely to use for initial diagnosis and prompt treatment of acute malaria. It should, however, be used for research and epidemiologic purposes in any malaria infection in the USA, to determine and confirm the infecting species.<xref ref-type="bibr" rid="article-27309.r8">[8]</xref>&#x000a0;All cases should also be evaluated for evidence of drug resistance, as per CDC guidelines.<xref ref-type="bibr" rid="article-27309.r9">[9]</xref></p>
      </sec>
      <sec id="article-27309.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>CDC recommends that the treatment of malaria should not be initiated until the diagnosis has been confirmed by laboratory testing. Treatment should be initiated immediately after the confirmation of malaria infection. Empirical treatment is, however, reserved only for extreme cases where there is a strong clinical suspicion with convincing exposure history, presence of severe disease, or an inability to diagnose malaria due to inadequate laboratory facilities.</p>
        <p>The treatment should be guided by three main factors: the infecting <italic toggle="yes">Plasmodium</italic> species, the clinical status of the patient, and drug susceptibility of infecting<italic toggle="yes"> Plasmodium</italic>, determined by the geographic region where the infection was acquired. Chloroquine sensitivity can be expected if the infection was acquired in Central America west of Panama Canal, Haiti, and the Dominican Republic. In a case when the diagnosis is strongly suspected, and it cannot be confirmed, or when there is no species determination possible, given the global spread of <italic toggle="yes">P.&#x000a0;falciparum</italic> resistant to chloroquine, the clinician should opt for a treatment option effective against chloroquine-resistant <italic toggle="yes">P. falciparum</italic>. CDC recommends making additional blood smears in infections with <italic toggle="yes">P. falciparum</italic> after initiating the treatment, to confirm adequate parasitological response (decrease in density) to treatment.</p>
        <p>Extended, evidence-based, and comprehensive guidelines for malaria management and optimal dosing of antimalarial medications can be found in the third edition of WHOs Guidelines for the treatment of malaria. Treatment and management algorithms for malaria in the USA are available on the CDC&#x000b4;s official website.</p>
        <p>
<bold>Uncomplicated Falciparum Malaria&#x000a0;</bold>
</p>
        <p>Uncomplicated falciparum malaria should be treated with one of the artemisinin-based combination therapies (ACT). Artemisinin-based combination therapy (ACT) is highly effective due to its effect on a broader range of parasite life cycles, causing faster parasite clearance and is therefore considered a drug of choice for uncomplicated malaria.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref>&#x000a0;The duration&#x000a0;of ACT treatment is 3 days. ACTs are also recommended for pregnant women in the second and third trimester but should be used during the first trimester only if other treatment options are not available. During the first trimester, a combination of quinine and clindamycin should be prescribed. In low transmission areas, gametocytocidal therapy (e.g., primaquine) is added to ACTs to reduce transmission potential (except pregnant women, infants younger than 6 months and women breastfeeding infants younger than 6 months).<xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
        <p>There are some other treatment options, although not as effective as ACTs, such as atovaquone-proguanil, quinine sulfate plus doxycycline, tetracycline, or clindamycin, and mefloquine. For chloroquine-sensitive<italic toggle="yes"> P. falciparum</italic> infections (including</p>
        <p>pregnant women), the drug of choice is chloroquine. However, any of the drug choices listed above for chloroquine-resistant strains can be used.&#x000a0;Treatment options are the same for the pediatric population, with doses adjusted by the patient&#x02019;s weight.&#x000a0;</p>
        <p>
<bold>Severe Falciparum Malaria</bold>
</p>
        <p>All patients diagnosed or with a strong suspicion with signs and symptoms of severe malaria should be promptly treated with parenteral antimalarial therapy. Effective, urgent, and appropriate treatment has the greatest impact on prognosis.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref>&#x000a0;</p>
        <p>Intravenous or intramuscular artesunate is the first-line treatment in all patients (including children, lactating women, and pregnant women in all trimesters) worldwide and should be used for at least 24 hours and until the oral medication is tolerated.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;Children should receive a higher dose (3 mg/kg BW per dose) of the artesunate to ensure the equivalent drug effect. The dose for larger children and adults is 2.4 mg/kg BW per dose. Three doses of intravenous artesunate should be given: one immediately, followed by a dose at 12 hours and 24 hours. &#x000a0;&#x000a0;</p>
        <p>If artesunate is not available, the recommended drug is artemether in preference to quinine. After the complete course of a 24 hour intravenous artesunate, a regimen of a follow-up drug should be completed. A full 3-day regimen of ACT is recommended. In returning traveler, the follow-on antimalarial medication needs to be other than the antimalarial medication taken for prophylaxis.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref>&#x000a0;</p>
        <p>Intravenous artesunate is currently not approved by the Food and Drug Administration (FDA) or commercially available in the U.S. but is available from CDC under an expanded-access investigational drug (IND) protocol. It is prepositioned at distribution sites throughout the USA and readily available after contacting CDC. Since severe malaria can progress rapidly, CDC offers guidance on oral treatment that can be used while waiting for IV artesunate to be delivered. They recommend interim treatment with oral artemether-lumefantrine (preferably), atovaquone-proguanil, quinine sulfate, or mefloquine. If a patient can not tolerate oral medications, administration after an antiemetic or via nasogastric tube should be considered.</p>
        <p>Patients with falciparum malaria should be admitted to the hospital due to the possibility of deterioration even after the effective treatment was initiated. If patients are determined to have uncomplicated malaria, they can be treated as outpatients after confirming that they can tolerate oral therapy, and the parasitemia has declined.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref>&#x000a0;Ideally, a patient with severe malaria should be admitted to an intensive-care unit or high dependency unit with close monitoring of clinical status, vital signs, consciousness level, and laboratory values.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r24">[24]</xref></p>
        <p>It is important to provide supportive therapy, such as glucose to maintain euglycemia and acetaminophen for fever control, careful, individualized fluid management as patients present with variable degrees of hypovolemia, acidosis, and acute kidney failure. Blood transfusion is sometimes indicated in severe anemias; benzodiazepines should be used for seizure control. However, prophylactic antiepileptic medications are not recommended, and empiric antibiotics should be used in children with severe malaria and adults with concurrent shock.<xref ref-type="bibr" rid="article-27309.r4">[4]</xref><xref ref-type="bibr" rid="article-27309.r22">[22]</xref><xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
      </sec>
      <sec id="article-27309.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other travel-related infections such as typhoid, viral hemorrhagic fevers (such as Ebola, Lassa fever, etc.), hepatitis, dengue, and other arboviruses, enteric fever, avian influenza, tuberculosis, MERS-CoV infections, HIV, meningitis, and encephalitis can resemble malaria. Non-tropical infections such as bacterial pneumonia, septicemia, and influenza should be excluded.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref><xref ref-type="bibr" rid="article-27309.r25">[25]</xref></p>
        <p>Cerebral malaria can mimic bacterial meningitis, measles, (locally prevalent) viral encephalitis, toxic syndromes, and intracranial vascular or mechanical events.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
      </sec>
      <sec id="article-27309.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with uncomplicated malaria, especially with timely diagnosis, treatment, and proper compliance, usually recover from malaria without consequences. The mortality rate for uncomplicated malaria is low, around 0.1%.<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r6">[6]</xref><bold>&#x000a0;</bold>The mortality&#x000a0;rate rises steeply once the patient develops signs and symptoms of severe <italic toggle="yes">falciparum</italic> malaria. Adults have higher mortality rates and more frequent multisystem involvement than children, with mortality rates being 18.5% and 9.7%, respectively.<xref ref-type="bibr" rid="article-27309.r20">[20]</xref>&#x000a0;The two main determinants reflecting the outcome for both adults and children were found to be the level of consciousness assessed by coma scales and the degree of metabolic acidosis, assessed clinically by breathing pattern or more precisely with measurement of bicarbonate, base deficit, and plasma lactate.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><bold>&#x000a0;</bold>While the general mortality of treated severe malaria is between 10% to 20%, the mortality in pregnant women reaches approximately 50%.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
      </sec>
      <sec id="article-27309.s11" sec-type="Complications">
        <title>Complications</title>
        <p>A distinct complication of<italic toggle="yes"> P. falciparum</italic> malaria is cerebral malaria (CM), a diffuse and symmetrical encephalopathy.<xref ref-type="bibr" rid="article-27309.r16">[16]</xref>&#x000a0;It is a clinical syndrome defined as an impaired consciousness (clinically determined as stated in Table 1) that cannot be attributed to other causes such as convulsions, hypoglycemia, sedative drugs, or other non-malarial causes and is associated with an unequivocal diagnosis of malarial infection. Due to several other possible causes of altered consciousness, the presence of retinopathy has been used in an attempt to increase the specificity of diagnosis of CM and improve the classification of severe malaria.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
        <p>Other possible complications, predominantly caused by <italic toggle="yes">P. falciparum</italic>, include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute kidney injury complicates up to 40% of<italic toggle="yes"> P. falciparum</italic> malaria.<xref ref-type="bibr" rid="article-27309.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Non-cardiogenic pulmonary edema, acute respiratory distress syndrome (ARDS), and hypoxia<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Electrolyte and fluid abnormalities<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Acid-base disturbances &#x02013; mostly acidosis and hyperlactatemia<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Hypoglycemia, often exacerbated by quinine therapy<xref ref-type="bibr" rid="article-27309.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Anemia, with the reduction in hemoglobin levels being proportional to disease severity and duration of illness before treatment<xref ref-type="bibr" rid="article-27309.r13">[13]</xref><xref ref-type="bibr" rid="article-27309.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Other hematological complications (delayed hemolytic anemia following artemisinin treatment, hyper-reactive malarial splenomegaly (HMS), and splenic rupture)<xref ref-type="bibr" rid="article-27309.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Blackwater fever and hemoglobinuria due to intravascular hemolysis in patients with severe clinical manifestations of falciparum malaria<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Profound thrombocytopenia is often associated with<italic toggle="yes"> P. falciparum</italic> infection, however, bleeding and disseminated intravascular coagulation (DIC) are rare.<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatic dysfunction<xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Shock and associated infections (such as <italic toggle="yes">Salmonella</italic> bacteriemia, aspiration pneumonia, nosocomial infections, etc.)<xref ref-type="bibr" rid="article-27309.r3">[3]</xref><xref ref-type="bibr" rid="article-27309.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Neurological sequelae (epilepsy, permanent focal deficits, etc.)<xref ref-type="bibr" rid="article-27309.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>The three most common complications occurring in children are cerebral malaria, severe anemia, and acidosis, either isolated or overlapping.<xref ref-type="bibr" rid="article-27309.r20">[20]</xref></p>
      </sec>
      <sec id="article-27309.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Although no intervention for preventing the infection is 100% effective, there are several different approaches available that can be used alone or in combination. Personal protective measures reduce the risk of exposure to infective mosquitoes, and chemoprophylaxis can aid in reducing the risk of a poor outcome if infected.<xref ref-type="bibr" rid="article-27309.r26">[26]</xref><bold>&#x000a0;</bold>A common approach usually applied is an &#x0201c;ABCD&#x0201d; of malaria &#x02013; A standing for awareness of the risk, B for bite avoidance, C for compliance with chemoprophylaxis, and D for diagnosis in case of fever. It is essential to consider traveler&#x000b4;s health (especially pregnancy, age, immunosuppression) when assessing the risk for developing severe malaria and choosing an appropriate antimalarial drug.<xref ref-type="bibr" rid="article-27309.r10">[10]</xref></p>
        <p>It is necessary to emphasize the importance of personal protective measures such as barrier clothing, insecticide-impregnated bed nets, application of effective mosquito repellent (higher percentage of active ingredient provides longer protection), and spraying the residence with insecticide. Products that contain 20%-40% of DEET (N, N-Diethyl-meta-toluamide), picaridin, oil of lemon eucalyptus or PMD (p-menthane-3,8-diol) and IR3535 are recommended. Behaviors to minimize exposure to mosquitos are also encouraged &#x02013; for instance, staying indoors from dusk till dawn, choosing screened accommodations.<xref ref-type="bibr" rid="article-27309.r9">[9]</xref><xref ref-type="bibr" rid="article-27309.r26">[26]</xref>&#x000a0;Indoor residual spraying and long-lasting insecticidal nets remain to be the most effective tools for malaria control and elimination, despite the emergence of insecticide-resistant <italic toggle="yes">Anopheles</italic> mosquitos.<xref ref-type="bibr" rid="article-27309.r27">[27]</xref><xref ref-type="bibr" rid="article-27309.r28">[28]</xref></p>
        <p>A standard recommendation for all travelers to endemic areas is strict compliance with the antimalarial drug. There are several different drug choices, prescribed after assessing individual&#x000b4;s risk (level of local transmission, duration of exposure, rural vs. urban travel, type of travel and season), travelers health status, present contraindications, level of parasite drug resistance (mostly chloroquine and mefloquine resistance) and traveler&#x02019;s preference based on schedule, cost and nature of possible side effects<bold>. </bold>There is an increasing problem with counterfeit and substandard medications being sold in several Sub-Saharan countries, and travelers should be advised to buy the needed medications before departure.<xref ref-type="bibr" rid="article-27309.r29">[29]</xref><xref ref-type="bibr" rid="article-27309.r10">[10]</xref><bold>&#x000a0;</bold>A complete list of recommendations for drug choice can be found on the CDCs website &#x02013; Malaria Information by Country.</p>
        <p>As pregnant women are at increased risk for severe malaria, the WHO and other organizations recommend not traveling to the endemic areas.<xref ref-type="bibr" rid="article-27309.r10">[10]</xref></p>
        <p>Travelers to the endemic areas, former residents of malaria-endemic areas and people diagnosed with malaria should be informed, as per Food and Drug Administration (FDA) recommendations, that they may not donate blood for 1 year after travel or 3 years after departing or revisiting the country or for 3 years after treatment, respectively.<xref ref-type="bibr" rid="article-27309.r9">[9]</xref></p>
        <p>Travelers should be informed that malaria can be fatal with delayed treatment, and one should, therefore, seek medical attention while abroad if symptoms of malaria develop and not fly back for treatment, as medical treatment may not be readily available on transit<bold>.</bold><xref ref-type="bibr" rid="article-27309.r9">[9]</xref></p>
      </sec>
      <sec id="article-27309.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Malaria vaccine would be an ideal tool to control, prevent, eliminate, and ultimately eradicate the disease.&#x000a0;The complexity of <italic toggle="yes">P. falciparum</italic> infection has hindered several attempts at developing an effective vaccine, yet the acquisition of partial immunity and successful treatment of malaria with purified immunoglobulins from semi-immune adults showed that the development of a vaccine is attainable. Researchers have identified several potential targets in the parasite&#x000b4;s infectious cycle. Currently, 20 vaccine candidates are undergoing clinical trials.<xref ref-type="bibr" rid="article-27309.r27">[27]</xref><bold>&#x000a0;</bold>The most promising and most advanced vaccine to be developed so far is a licensed RTS, S subunit vaccine (RTS, S/ASO1), targeting the pre-erythrocytic stage of infection, thus preventing hepatocyte infection and parasite development, consequently limiting RBC invasion. It consists of a recombinant protein of the <italic toggle="yes">P. falciparum</italic> circumsporozoite protein (CSP) conjugated to the hepatitis B surface antigen.<xref ref-type="bibr" rid="article-27309.r27">[27]</xref>&#x000a0;RTS, S/ASO1, the first malaria vaccine which has received regulatory approval for human use, was used to start the first routine malaria vaccination program in Africa &#x02013; a pilot study in Malawi in April 2019, which has since expanded to Kenya and Ghana. The pilot study is planned to last about 50 months and to enroll 720 000 children in vaccination and control clusters, however several safety concerns, that are now being investigated in the pilot study, have already been identified in phase III trials:&#x000a0; higher risk of meningitis, cerebral malaria and doubled female mortality. If no serious safety concern is determined in the first 24 months of trial, the pilot study will run its full course before any decision will be made about its broader use in endemic countries.<xref ref-type="bibr" rid="article-27309.r30">[30]</xref></p>
        <p>There has been an emergence of a (widely used) pyrethroid insecticide-resistant malaria vector population, causing extensive research with their first results suggesting a better effect of long-lasting insecticidal nets treated with PBO (piperonyl butoxide) instead of pyrethroid laced nets.<xref ref-type="bibr" rid="article-27309.r28">[28]</xref></p>
      </sec>
      <sec id="article-27309.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Most cases of malaria in the U.S. are imported and could, therefore, be avoided with appropriate personal protective measures and compliance with prescribed chemoprophylaxis. Health care providers on all levels must be educated not only on the diagnosis and treatment of malaria but especially on the importance of prevention. They should be able to provide enough information to travelers at risk. Travelers to the endemic areas should obtain appropriate clothing, insecticides, and other protective gear based on the information offered by health care providers and CDC. Collaboratively, a physician and a pharmacist, should decide on, recommend and prescribe appropriate chemoprophylaxis, considering traveler's personal preferences, time of travel, current health status, risk factors, drug-drug interactions, and possible contraindications, while emphasizing the importance of compliance with the drug-taking regimen.&#x000a0;</p>
        <p>The crucial issue in the diagnosis and treatment of malaria is the consideration of the possibility of diagnosis. Expert advice from an infectious disease or travel medicine specialist should be sought once malaria is a suspected diagnosis, especially in the setting of severe disease.<xref ref-type="bibr" rid="article-27309.r24">[24]</xref>&#x000a0;The execution of a microscopic analysis of a stained blood smear often depends on several factors such as laboratory equipment, quality of reagents, and laboratorian expertise. Laboratorians should, therefore, be trained in the preparation and analysis of blood-smears to diagnose a malarial infection correctly. The results need to be communicated back to the physician as soon as possible. All laboratory-confirmed cases of malaria should be reported to CDC to help with their surveillance efforts.<bold>&#x000a0;</bold>Healthcare providers that are a part of the interprofessional team (nurses, respiratory therapists, physicians, etc.) managing patients with severe malaria in critical or intensive care units, should be educated on early recognition of complications.</p>
      </sec>
      <sec id="article-27309.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27309&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27309">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/plasmodium-falciparum-malaria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27309">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27309/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27309">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27309.s16">
        <fig id="article-27309.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Life Cycle of the Malaria Parasite Contributed by Wikimedia Commons, National Institutes of Health (NIH) (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Life_Cycle_of_the_Malaria_Parasite" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27309.s17">
        <fig id="article-27309.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Mosquito-Borne Diseases. Mosquitoes are carriers of various diseases, including Zika, dengue fever, West Nile fever, chikungunya, yellow fever, and malaria. National Institute of Allergy and Infectious Diseases, National Institutes of Health</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="28526339553_e1691dcb2d_k" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27309.s18">
        <fig id="article-27309.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Blood smear malaria Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="malaria" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27309.s19">
        <fig id="article-27309.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Diagnostic criteria for severe P. falciparum malaria Contributed by Lara Zekar, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1-LaraZekarMD" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27309.s20">
        <fig id="article-27309.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Rings of P. falciparum in a thin blood smear. Contributed by the Center for Disease Control and Prevention (CDC)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Rings_of_P._falciparum_in_a_thin_blood_smear" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27309.s21">
        <title>References</title>
        <ref id="article-27309.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snow</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Global malaria eradication and the importance of Plasmodium falciparum epidemiology in Africa.</article-title>
            <source>BMC Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>03</day>
            <volume>13</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">25644195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Malaria.</article-title>
            <source>Clin Lab Med</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-129</page-range>
            <pub-id pub-id-type="pmid">20513543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breman</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Eradicating malaria.</article-title>
            <source>Sci Prog</source>
            <year>2009</year>
            <volume>92</volume>
            <issue>Pt 1</issue>
            <fpage>1</fpage>
            <page-range>1-38</page-range>
            <pub-id pub-id-type="pmid">19544698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Pyae Phyo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woodrow</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Malaria.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Apr</month>
            <day>21</day>
            <volume>391</volume>
            <issue>10130</issue>
            <fpage>1608</fpage>
            <page-range>1608-1621</page-range>
            <pub-id pub-id-type="pmid">29631781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meibalan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Biology of Malaria Transmission.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>7</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27836912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milner</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Malaria Pathogenesis.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>02</day>
            <volume>8</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28533315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drakeley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bousema</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sauerwein</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Targett</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion.</article-title>
            <source>Trends Parasitol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>424</fpage>
            <page-range>424-30</page-range>
            <pub-id pub-id-type="pmid">16846756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mace</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Arguin</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Malaria Surveillance - United States, 2015.</article-title>
            <source>MMWR Surveill Summ</source>
            <year>2018</year>
            <month>May</month>
            <day>04</day>
            <volume>67</volume>
            <issue>7</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">29723168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerstenlauer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recognition and Management of Malaria.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-260</page-range>
            <pub-id pub-id-type="pmid">31027664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Acremont</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Malaria prevention in travelers.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>637</fpage>
            <page-range>637-54</page-range>
            <pub-id pub-id-type="pmid">22963775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cella</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Baia-da-Silva</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Melo</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Tadei</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Sampaio</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Pimenta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacerda</surname>
                <given-names>MVG</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Do climate changes alter the distribution and transmission of malaria? Evidence assessment and recommendations for future studies.</article-title>
            <source>Rev Soc Bras Med Trop</source>
            <year>2019</year>
            <volume>52</volume>
            <fpage>e20190308</fpage>
            <pub-id pub-id-type="pmid">31800921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dondorp</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smithuis</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Woodrow</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seidlein</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>How to Contain Artemisinin- and Multidrug-Resistant Falciparum Malaria.</article-title>
            <source>Trends Parasitol</source>
            <year>2017</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>353</fpage>
            <page-range>353-363</page-range>
            <pub-id pub-id-type="pmid">28187990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <article-title>Severe malaria.</article-title>
            <source>Trop Med Int Health</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>19 Suppl 1</volume>
            <fpage>7</fpage>
            <page-range>7-131</page-range>
            <pub-id pub-id-type="pmid">25214480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fried</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Malaria during Pregnancy.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>7</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28213434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>ter Kuile</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Nosten</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McGready</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Asamoa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brabin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and burden of malaria in pregnancy.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-104</page-range>
            <pub-id pub-id-type="pmid">17251080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Anaemia and malaria.</article-title>
            <source>Malar J</source>
            <year>2018</year>
            <month>Oct</month>
            <day>19</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>371</fpage>
            <pub-id pub-id-type="pmid">30340592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bernabeu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babar</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Rogerson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Seydel</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Lavstsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lusingu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rathod</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Aitchison</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of Plasmodium falciparum <italic>var</italic> Signatures Contributing to Severe Malaria in African Children and Indian Adults.</article-title>
            <source>mBio</source>
            <year>2019</year>
            <month>Apr</month>
            <day>30</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">31040236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plewes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leopold</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kingston</surname>
                <given-names>HWF</given-names>
              </name>
              <name>
                <surname>Dondorp</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Malaria: What's New in the Management of Malaria?</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-60</page-range>
            <pub-id pub-id-type="pmid">30712767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beeson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-71</page-range>
            <pub-id pub-id-type="pmid">11915943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wassmer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Rathod</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arevalo-Herrera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duraisingh</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Investigating the Pathogenesis of Severe Malaria: A Multidisciplinary and Cross-Geographical Approach.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>93</volume>
            <issue>3 Suppl</issue>
            <fpage>42</fpage>
            <page-range>42-56</page-range>
            <pub-id pub-id-type="pmid">26259939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>GBD</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>EJG</given-names>
              </name>
              <name>
                <surname>Farias</surname>
                <given-names>GMN</given-names>
              </name>
              <name>
                <surname>Daher</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Kidney involvement in malaria: an update.</article-title>
            <source>Rev Inst Med Trop Sao Paulo</source>
            <year>2017</year>
            <volume>59</volume>
            <fpage>e53</fpage>
            <pub-id pub-id-type="pmid">28793022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fletcher</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Beeching</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Malaria.</article-title>
            <source>J R Army Med Corps</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>158</fpage>
            <page-range>158-66</page-range>
            <pub-id pub-id-type="pmid">24109136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sypniewska</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duda</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Althaus</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Althaus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Genton</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis.</article-title>
            <source>BMC Med</source>
            <year>2017</year>
            <month>Aug</month>
            <day>03</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <pub-id pub-id-type="pmid">28768513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalloo</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Shingadia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Beeching</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Whitty</surname>
                <given-names>CJM</given-names>
              </name>
              <name>
                <surname>Chiodini</surname>
                <given-names>PL</given-names>
              </name>
              <collab>PHE Advisory Committee on Malaria Prevention in UK Travellers</collab>
            </person-group>
            <article-title>UK malaria treatment guidelines 2016.</article-title>
            <source>J Infect</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>635</fpage>
            <page-range>635-649</page-range>
            <pub-id pub-id-type="pmid">26880088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scaggs Huang</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Schlaudecker</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Fever in the Returning Traveler.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>163</fpage>
            <page-range>163-188</page-range>
            <pub-id pub-id-type="pmid">29406974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Schlagenhauf</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prevention of malaria in long-term travelers.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Nov</month>
            <day>08</day>
            <volume>296</volume>
            <issue>18</issue>
            <fpage>2234</fpage>
            <page-range>2234-44</page-range>
            <pub-id pub-id-type="pmid">17090770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frimpong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kusi</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ofori</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ndifon</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Novel Strategies for Malaria Vaccine Design.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>2769</fpage>
            <pub-id pub-id-type="pmid">30555463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Killeen</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ranson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Insecticide-resistant malaria vectors must be tackled.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Apr</month>
            <day>21</day>
            <volume>391</volume>
            <issue>10130</issue>
            <fpage>1551</fpage>
            <page-range>1551-1552</page-range>
            <pub-id pub-id-type="pmid">29655495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brower</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Counterfeit and substandard malaria drugs in Africa.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1026</fpage>
            <page-range>1026-1027</page-range>
            <pub-id pub-id-type="pmid">28948928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27309.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fisker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rkman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benn</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>WHO's rollout of malaria vaccine in Africa: can safety questions be answered after only 24 months?</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Jan</month>
            <day>24</day>
            <volume>368</volume>
            <fpage>l6920</fpage>
            <pub-id pub-id-type="pmid">31980436</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
